Moreover, in comparison to a conventional DNA plasmid, intradermal administration of SIN-HER2/neu DNA replicons required 80% less DNA to elicit robust antibody responses and protection against tumor challenges in BALB/c mice (Lachman et al., 2001). This evidence concerns the gene ERBB2 and neoplasm.